Coherus BioSciences, Inc.

Coherus BioSciences, Inc.verified

CHRS

Price:

$1.64

Market Cap:

$188.15M

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biolo...[Read more]

Industry

Biotechnology

IPO Date

2014-11-06

Stock Exchange

NASDAQ

Ticker

CHRS

The PE Ratio as of June 2024 (TTM) for Coherus BioSciences, Inc. (CHRS) is -2.22

According to Coherus BioSciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.22. This represents a change of 78.09% compared to the average of -1.25 of the last 4 quarters.

Coherus BioSciences, Inc. (CHRS) Historical PE Ratio (quarterly & annually)

How has CHRS PE Ratio performed in the past?

The mean historical PE Ratio of Coherus BioSciences, Inc. over the last ten years is -0.32. The current -2.22 PE Ratio has changed 69.92% with respect to the historical average. Over the past ten years (40 quarters), CHRS's PE Ratio was at its highest in in the December 2020 quarter at 32.33. The PE Ratio was at its lowest in in the September 2014 quarter at -12.84.

Quarterly (TTM)
Annual

Average

-0.32

Median

-1.92

Minimum

-9.27

Maximum

13.97

Coherus BioSciences, Inc. (CHRS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Coherus BioSciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 148.97%

Maximum Annual PE Ratio = 13.97

Minimum Annual Increase = -596.90%

Minimum Annual PE Ratio = -9.27

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.32-29.98%
2022-1.88-52.12%
2021-3.93-141.89%
20209.39-32.80%
201913.97-596.90%
2018-2.8143.16%
2017-1.96-78.81%
2016-9.27142.70%
2015-3.82148.97%
2014-1.53-63.94%

Coherus BioSciences, Inc. (CHRS) Average PE Ratio

How has CHRS PE Ratio performed in the past?

The current PE Ratio of Coherus BioSciences, Inc. (CHRS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-2.38

5-year avg

3.24

10-year avg

-0.32

Coherus BioSciences, Inc. (CHRS) PE Ratio vs. Peers

How is CHRS’s PE Ratio compared to its peers?

Coherus BioSciences, Inc.’s PE Ratio is less than Assembly Biosciences, Inc. (-1.62), less than Spero Therapeutics, Inc. (2.93), less than Achilles Therapeutics plc (-0.56), less than Instil Bio, Inc. (-0.53), less than Neoleukin Therapeutics, Inc. (-0.98), less than NextCure, Inc. (-0.63), greater than Nuvation Bio Inc. (-9.32), less than CytomX Therapeutics, Inc. (6.80), less than Bolt Biotherapeutics, Inc. (-0.46), greater than Gracell Biotechnologies Inc. (-12.56),

Build a custom stock screener for Coherus BioSciences, Inc. (CHRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coherus BioSciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Coherus BioSciences, Inc. (CHRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Coherus BioSciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Coherus BioSciences, Inc.'s PE Ratio?

How is the PE Ratio calculated for Coherus BioSciences, Inc. (CHRS)?

What is the highest PE Ratio for Coherus BioSciences, Inc. (CHRS)?

What is the 3-year average PE Ratio for Coherus BioSciences, Inc. (CHRS)?

What is the 5-year average PE Ratio for Coherus BioSciences, Inc. (CHRS)?

How does the current PE Ratio for Coherus BioSciences, Inc. (CHRS) compare to its historical average?